key: cord-1019948-tptwr151
authors: Eckert, Linda O.; Jones, Christine E.; Kachikis, Alisa; Bardají, Azucena; Tavares Da Silva, Fernanda; Absalon, Judith; Rouse, Caroline E.; Khalil, Asma; Cutland, Clare L.; Kochhar, Sonali; Munoz, Flor M.
title: Obstetrics Risk Assessment: Evaluation of Selection Criteria for Vaccine Research Studies in Pregnant Women
date: 2020-05-11
journal: Vaccine
DOI: 10.1016/j.vaccine.2020.05.022
sha: 68986febd925e135bb10b5d3157e830a728d46d9
doc_id: 1019948
cord_uid: tptwr151

Vaccines designed for use in pregnancy and vaccine trials specifically involving pregnant women are rapidly expanding. One of the key challenges in designing maternal immunization trials is that developing exclusion criteria requires understanding and quantifying the background risk for adverse pregnancy outcomes in the pregnancy being studied, which can occur independent of any intervention and be unrelated to vaccine administration. The Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project has developed and published case definitions and guidelines for data collection, analysis, and evaluation of maternal immunization safety in trials involving pregnant women. Complementing this work, we sought to understand how to best assess obstetric risk of adverse outcomes and differentiate it from the assessment of vaccine safety. Quantification of obstetric risk is based on prior and current obstetric, and maternal medical history. We developed a step-wise approach to evaluate and quantify obstetric and maternal risk factors in pregnancy based on review of published literature and guidelines, and critically assessed these factors in the context of designing inclusion and exclusion criteria for maternal vaccine studies. We anticipate this risk assessment evaluation may assist clinical trialists with study design decisions, including selection of exclusion criteria for vaccine trials involving pregnant women, consideration of sub-group classification, such as high or low risk subjects, or schedule considerations, such as preferred trimester of gestation for an intervention during pregnancy. Additionally, this tool may be utilized in data stratification at time of study analyses.

Vaccines designed for use in pregnancy and vaccine trials specifically involving pregnant women are rapidly expanding. One of the key challenges in designing maternal immunization trials is that developing exclusion criteria requires understanding and quantifying the background risk for adverse pregnancy outcomes in the pregnancy being studied, which can occur independent of any intervention and be unrelated to vaccine administration.

The Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project has developed and published case definitions and guidelines for data collection, analysis, and evaluation of maternal immunization safety in trials involving pregnant women. Complementing this work, we sought to understand how to best assess obstetric risk of adverse outcomes and differentiate it from the assessment of vaccine safety. Quantification of obstetric risk is based on prior and current obstetric, and maternal medical history. We developed a step-wise approach to evaluate and quantify obstetric and maternal risk factors in pregnancy based on review of published literature and guidelines, and critically assessed these factors in the context of designing inclusion and exclusion criteria for maternal vaccine studies. We anticipate this risk assessment evaluation may assist clinical trialists with study design decisions, including selection of exclusion criteria for vaccine trials involving pregnant women, consideration of subgroup classification, such as high or low risk subjects, or schedule considerations, such as preferred trimester of gestation for an intervention during pregnancy. Additionally, this tool may be utilized in data stratification at time of study analyses.

Words: 240

Immunization of pregnant women, or maternal immunization, is a practical, evidence-based strategy to prevent severe morbidity and reduce mortality in mothers, neonates and young infants. 1 Vaccine research requires careful assessment of safety and efficacy in all study participants. When administering a vaccine to pregnant women, safety evidence must encompass the mother, the developing fetus, and subsequently the neonate, infant, and the child.

Accumulating this safety data with the ability to reliably measure potential adverse events of interest is improved by standardization of definitions of potential adverse events and data collection in a manner that is applicable across all resource settings.

With the goal towards broadening future maternal immunization trials, in 2014 the World Health Organization (WHO) convened a stakeholder meeting where key obstetric and neonatal terms were identified and prioritized for standardization of definitions. 2 The Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project was established, and since 2014, GAIA, 3 utilizing Brighton Collaboration methodology, has developed and published case definitions and guidelines for data collection, analysis, and presentation of maternal immunization safety data in trials involving pregnant women for twenty-one obstetric and neonatal terms. 4 These case definitions and tools have been adopted in recent maternal immunization studies to evaluate maternal and neonatal outcomes, including use in a recent Phase III maternal immunization trial. 5, 6 Clinical trials in pregnant women are complex because, even in healthy pregnant women, adverse obstetric outcomes (such as fetal abnormalities, preterm birth, miscarriage, growth restriction and preeclampsia) occur and thus can also be anticipated to occur in the setting of a clinical trial, independent of the intervention. Many of the women who develop these problems do not have risk factors, making complications which occur in pregnancy difficult to predict. The risk of pregnancy complications can be, in part, informed by the background rates of these events in any given population. However, data on background rates of adverse pregnancy outcomes may not always be available. 7 Hence, it is challenging for clinical investigators to know which prior and current pregnancy risk factors are appropriate study exclusion criteria. The selection of criteria for inclusion or exclusion of subjects in the study is among the more critical study design decisions. In early phase clinical trials, it is common to enroll the healthiest populations to minimize risk. As the product profile is better defined in later stage studies, a broader group of individuals are generally enrolled. By Phase 3, study participants more closely mirror the target population for the vaccine and are enrolled in larger numbers, and it is typical to have fewer exclusion criteria.

Currently, standardized guidance is lacking that may inform the choice of inclusion and exclusion of pregnant participants for any of the vaccine trial development phases.

Understanding the obstetric risk of common inclusion and exclusion criteria may facilitate not only a more informed choice of inclusion and exclusion criteria in these clinical studies of vaccines in pregnant women, but also a tailored use of these criteria based on the phase of development (I-IV) of the vaccine.

In an effort to assist clinical investigators in maternal immunization trials, a GAIA Working Group with broad geographic and specialty representation was formed to evaluate the selection criteria that have previously been used to select women for participation in clinical trials of vaccines in pregnancy and to develop a strategy to help assess obstetric risks for designing maternal immunization trials. The overriding aim is to develop a consolidated evaluation and quantification of risk factors in pregnancy that would be useful to investigators in designing vaccine trials involving pregnant women. While this assessment is designed specifically for vaccine trials, it may also offer applicability for other interventions being assessed in pregnant women.

We used several methods to identify the criteria previously used for inclusion and exclusion of study participants in studies of vaccines in pregnancy. We searched the National Institutes of Health U.S. National Library of Medicine ClinicalTrials.gov database to to identify current, completed or withdrawn studies of vaccines in pregnant women. Studies were identified the search terms "pregnancy", "pregnant women", "maternal", "mothers", "immunization", "vaccination", "vaccine", "vaccines", and a combination of the term "pregnancy" or "maternal" with specific vaccines including "influenza", "tetanus", "Tdap", "pertussis", "respiratory syncytial virus" , "RSV", "group B streptococcus", "GBS", "pneumococcal", "pneumococcus", "meningitis", "meningococcal", "hepatitis", "pandemic", "seasonal". All relevant studies listed in the ClinTrials.gov through 07 October 2018 were included. We identified a total of 43 interventional and 21 observational studies of vaccines in pregnant women. We abstracted and reviewed the complete list of inclusion and exclusion criteria utilized in each of these studies.

We used similar search terms to conduct a literature search (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) in Medline, Embase, and leading textbooks to identify and catalogue published US and international guidelines used to classify pregnancies based on obstetric risk, and to identify guidelines for referral from a mid level provider to a high risk provider, or from a low risk facility to a high risk or tertiary facility.

We chose to include guidelines for referral in our approach because high risk prenatal referral guidelines represent what pregnancy care providers utilize to judge increased obstetric risk, and could inform trial design. Lastly, we conducted a literature review searching for articles listing obstetric risk factors as they pertained to clinical trials and vaccine trials.

Based on these findings, we derived a comprehensive matrix of exclusion criteria and obstetric conditions used to determine the risk of adverse outcomes during pregnancy. We classified these into broad categories, including past obstetric and gynaecological history, family history, medical and obstetric conditions during the current pregnancy and fetal conditions. Individual tables were then derived from this matrix for interventional studies classified by development phase (phase I to IV), observational studies, and practice guidelines, detailing the number of studies or guidelines where each potential risk factor was cited. Based on this matrix, we created a heat map to indicate frequency of occurrence.

After creating this matrix, we identified the most commonly listed exclusion criteria in clinical studies conducted in pregnant women, and considered the most common factors that could increase the risk for adverse outcomes during pregnancy. In order to provide more detail about the risk of adverse events in the current pregnancy associated with these exclusion criteria, we looked for studies documenting risk of various adverse pregnancy outcomes when the identified condition listed as an exclusion criteria occured during pregnancy.

Sixty three maternal immunization studies (25 Phase I/II, 7 Phase III, 11 post licensure, 21 observational) were identified from ClinicalTrials.gov (Appendix 1)and six practice guidelines were identified by obstetric experts. Table 1 Table 1) . Table 1 presents the frequencies that each of these factors were listed as exclusion criteria in different phases of clinical trials of vaccines in pregnancy and in relevant practice guidelines. Table 2 summarizes the risks of adverse outcomes for some of the factors.

In addition to the Table 2 summary of risk factors, we used our literature search to provide more detailed and highly referenced text discussions of these risk factors in Appendix 3. Due to the length of this discussion on these 15 most common exclusion criteria (listed in Box 1), this text discussion is presented in Appendix 3 as Supplemental Material.

The purpose of this project was to provide clinical researchers with data that may be helpful in selecting appropriate exclusion criteria for maternal vaccine clinical trials. We created a comprehensive matrix of exclusion and risk factors delineating the frequency of exclusion criteria and risk factors used across the spectrum of clinical studies of vaccines in pregnancy.

The selection of subjects and the selection of the risk threshold that is acceptable will depend on the type of vaccine being used, the phase of the clinical study, and various other factors such as the perception of risk and potential real risks in a given population. We sought to catalogue and provide specific data on adverse pregnancy outcomes associated with the more commonly Complications in pregnancy can occur even in normal low risk pregnancies, and all medicinal products including vaccines can have side effects -although not everyone has them. In clinical studies where there is a placebo or comparator group, similar frequency of obstetric adverse events is expected to occur in both groups. For Phase III trials, ideally the study population should mirror the target population. Exclusion criteria based on selection of women with low risk for obstetric complications can be too restrictive and limit the ability to assess safety of the vaccine in the populations who need it the most. Additionally, exclusion criteria may act indirectly to alter study results by excluding participants who would otherwise be at increased risk for a condition. For example, Group B Streptococcus (GBS) is considered an important cause of stillbirth and preterm labor globally. Eliminating pregnant women with a prior stillbirth or prior preterm labor from participation in clinical research on GBS may also impact efficacy results of an intervention and may add bias to the study. 58, 59 In fact, inclusion of "higher risk" populations may better allow the ability to demonstrate differences between vaccine and control and potentially make a vaccine available to women sooner.

Researchers should determine what population they will evaluate (such as healthy and at risk), Using the information provided in this manuscript and its supplements may actually be most useful for the design of the studies that are currently being planned for some emerging infections. This is because there is a need to be more inclusive (with less restrictive criteria) which may be associated with the occurrence of adverse events linked to the population being evaluated.

However, we cannot choose to leave pregnant women out of the opportunity to benefit from vaccines that are being given to or studied in the general population, such as Ebola or those to protect against coronavirus disease 2019 (COVID- 19) . In fact, the inclusion of pregnant and lactating women in studies of vaccines in epidemic or pandemic settings has been a topic of debate and publication even before the current COVID-19 pandemic. 55, [60] [61] [62] This approach has several strengths. To our knowledge, this delination and frequency mapping of exclusion criteria based on a comprehensive search of prior maternal immunization trials has not been done previously. Adding stratification by study phase offers additional information for trialists. Including referral guidelines for high risk pregnancies in the matrix adds an obstetric provider perception of risk factors for adverse events. Another unique aspect of our approach and perhaps of the most useful to trialists may be to offer more quantitative information about these factors for the most commonly listed exclusion criteria.

This obstetrics risk assessment method we present here is not exhaustive nor is it meant to be prescriptive. This tool will not replace the need for detailed literature reviews about potential risk factors and exclusion criteria for specific products in pregnant populations, nor will it replace the need for using background rates of adverse events to assess safety. It is not designed to replace the clinical acumen and knowledge base that is offered by involving experienced obstetric providers and vaccine evaluators in trial design of vaccines in pregnancy. However, given that a standardized approach to the selection of participants in studies of vaccines in pregnancy is necessary, this information may serve to help clinical researchers reassess how conservative they need to be as a product progresses in development. The balance between deciding exclusion criteria and choosing a study population that mirrors the general population is complex. As clinical trials for vaccines specifically designed for an indication in pregnant women are novel, initial early phase trials may have more strict exclusion criteria. However, ongoing reassessment of criteria for inclusion in these and other protocols where pregnant women are study subjects will be imperative as data on background rates of expected obstetric events and safety information from epidemiologic studies and maternal immunization trials become more widely available. 

Who's the Target: Mother or Baby?

Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions

Global alignment of immunization safety assessment in pregnancy -The GAIA project

Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women

The Fourth International Neonatal and Maternal Immunization Symposium

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants

Immunization in pregnancy clinical research in low-and middle-income countries -Study design, regulatory and safety considerations

Evaluating the quality of care for severe pregnancy complications: the WHO near-miss approach for maternal health

Advanced maternal age and pregnancy outcomes: a multicountry assessment

Pregnancy and childbirth outcomes among adolescent mothers: a World Health Organization multicountry study

The impact of early age at first childbirth on maternal and infant health. Paediatric and perinatal epidemiology

Pregnancy in Adolescence: Is It an Obstetrical Risk?

Adverse Maternal and Neonatal Outcomes in Adolescent Pregnancy

Obstetric and perinatal outcomes of teenage pregnancies in Thailand

Moderate alcohol intake in pregnancy and the risk of spontaneous abortion

Moderate alcohol intake during pregnancy and the risk of stillbirth and death in the first year of life

Chronic hypertension and the risk for adverse pregnancy outcome after superimposed pre-eclampsia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and

Maternal complications in women with chronic hypertension: a population-based cohort study

Management of mild chronic hypertension during pregnancy: a review

Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis

Severe preeclampsia in the second trimester: recurrence risk and long-term

Pre-eclampsia in the second pregnancy: does previous outcome matter?

Risk of recurrent stillbirth: systematic review and meta-analysis

Unexplained fetal death: are women with a history of fetal loss at higher risk? The Australian &

Racial disparities in stillbirth risk across gestation in the United States

Group SCRNW. Association between stillbirth and risk factors known at pregnancy confirmation

102: management of stillbirth

Recurrence risk for preterm delivery

Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis

Obstetrical Complications Associated with Thrombophilias

Williams Obstetrics 2014: 1118. 34. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia

Prevalence and Complications of Pregestational and Gestational Diabetes in Saudi Women: Analysis from Riyadh Mother and Baby Cohort Study (RAHMA)

Population-level factors associated with maternal mortality in the United States

Global estimates of the prevalence of hyperglycaemia in pregnancy

The relative contribution of prepregnancy overweight and obesity, gestational weight gain, and IADPSG-defined gestational diabetes mellitus to fetal overgrowth

Preeclampsia and diabetes

Sudden fetal death in women with well-controlled, intensively monitored gestational diabetes

Diabetic-associated stillbirth: incidence, pathophysiology, and prevention

The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis

The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis

Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis

Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis

Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of

Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years

Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop

Key steps forward for maternal immunization: Policy making in action

Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments

The challenges of pregnancy in clinical trials for vaccines

Research on vaccines during pregnancy: protocol design and assessment of safety

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine 2019. 56. ''21st Century Cures Act''. An Act to accelerate the discovery, development, and delivery of 21st century cures, and for other purposes

Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses. Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020

7) FVL, PIH 2.2 (1.5-3.3) Plac ABR, FVL 4.7 (1.1-19.6) PIH, ACA 2.7 (1.Risk Assessment: Evaluation of Selection Criteria for Vaccine Research Studies in Pregnant Women 1. Critical Assessment for Choosing Exclusion Criteria in Vaccine Trials involving Pregnant women

Obstetric and maternal risk factors in pregnancy quantified based on review of published literature

Heat Map Matrix of Obstetric Exclusion Criteria based on Phase of Trial

Obstetric Risk Assessment facilitates inclusion criteria choice in maternal immunization trials

Received no personal funding for these activities Christine E Jones: Investigator for clinical trials done on behalf of her institutions, sponsored by vaccine manufacturers, but receives no personal funding for these activities

Employee of the GSK group of companies. FTDS owns restricted shares from the GSK group of companies Judith Absalon: Employee of Pfizer Caroline E. Rouse: None Asma Khalil: Chief Investigator and local principal Investigator for GSK and Novavax Vaccines studies Clare L Cutland: Consultant to Pfizer on GBS, maternal immunisation projects. Institutional support for maternal clinical vaccine trials from BMGF, Pfizer, Novavax. Institutional support for training from Sanofi Pasteur Institutional Grants from BMGF, Pfizer for maternal immunisation projects